Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Burrell

Showing results (221-230 of 381) with videos related to

Pageof 39
Sort By:
Ageing Research Reviews|July 7, 2026
Assessing the relationships between frailty, sarcopenia and Alzheimer's disease biomarkers: a scoping reviewAndrew Lh Huynh, Scott Wrigley, David Ward, et al.
American Journal of Physiology. Lung Cellular and Molecular Physiology|May 5, 2020
Rigor before speculation in COVID-19 therapyPaul A Welling, Daniel Batlle, James Brian Byrd, et al.
Hypertension (Dallas, Tex. : 1979)|November 1, 1995
Attenuation of genetic hypertension after short-term vasopressin V1A receptor antagonismL M Burrell, P A Phillips, J Risvanis, et al.
Beilstein Journal of Organic Chemistry|March 17, 2012
Synthesis of fused tricyclic amines unsubstituted at the ring-junction positions by a cascade condensation, cyclization, cycloaddition then decarbonylation strategyIain Coldham, Adam J M Burrell, Hélène D S Guerrand, et al.
The American Journal of Physiology|August 5, 1998
Long-term effects of nonpeptide vasopressin V2 antagonist OPC-31260 in heart failure in the ratL M Burrell, P A Phillips, J Risvanis, et al.
American Journal of Physiology. Lung Cellular and Molecular Physiology|August 4, 2009
Organic dust exposure alters monocyte-derived dendritic cell differentiation and maturationJill A Poole, Geoffrey M Thiele, Neil E Alexis, et al.
Clinical and Experimental Hypertension (New York, N.Y. : 1993)|March 6, 2004
Cardiorenal protective effects of vasopeptidase inhibition with omapatrilat in hypertensive transgenic (mREN-2)27 ratsSally A Mifsud, Louise M Burrell, Eiji Kubota, et al.
Hypertension (Dallas, Tex. : 1979)|June 1, 1994
Blood pressure-lowering effect of an orally active vasopressin V1 receptor antagonist in mineralocorticoid hypertension in the ratL M Burrell, P A Phillips, J M Stephenson, et al.
Clinical and Experimental Pharmacology & Physiology|March 1, 1994
Vascular endothelin responsiveness and receptor characteristics in vitro and effects of endothelin receptor blockade in vivo in cyclosporin hypertensionP A Phillips, K A Rolls, L M Burrell, et al.
Current Hypertension Reports|November 22, 2001
Evidence for cardioprotective, renoprotective, and vasculoprotective effects of vasopeptidase inhibitors in diseaseE Kubota, R G Dean, R A Hubner, et al.
Pageof 39

Showing results (221-230 of 381) with videos related to

Sort By:
Pageof 39
Ageing Research Reviews|July 7, 2026
Assessing the relationships between frailty, sarcopenia and Alzheimer's disease biomarkers: a scoping reviewAndrew Lh Huynh, Scott Wrigley, David Ward, et al.
American Journal of Physiology. Lung Cellular and Molecular Physiology|May 5, 2020
Rigor before speculation in COVID-19 therapyPaul A Welling, Daniel Batlle, James Brian Byrd, et al.
Hypertension (Dallas, Tex. : 1979)|November 1, 1995
Attenuation of genetic hypertension after short-term vasopressin V1A receptor antagonismL M Burrell, P A Phillips, J Risvanis, et al.
Beilstein Journal of Organic Chemistry|March 17, 2012
Synthesis of fused tricyclic amines unsubstituted at the ring-junction positions by a cascade condensation, cyclization, cycloaddition then decarbonylation strategyIain Coldham, Adam J M Burrell, Hélène D S Guerrand, et al.
The American Journal of Physiology|August 5, 1998
Long-term effects of nonpeptide vasopressin V2 antagonist OPC-31260 in heart failure in the ratL M Burrell, P A Phillips, J Risvanis, et al.
American Journal of Physiology. Lung Cellular and Molecular Physiology|August 4, 2009
Organic dust exposure alters monocyte-derived dendritic cell differentiation and maturationJill A Poole, Geoffrey M Thiele, Neil E Alexis, et al.
Clinical and Experimental Hypertension (New York, N.Y. : 1993)|March 6, 2004
Cardiorenal protective effects of vasopeptidase inhibition with omapatrilat in hypertensive transgenic (mREN-2)27 ratsSally A Mifsud, Louise M Burrell, Eiji Kubota, et al.
Hypertension (Dallas, Tex. : 1979)|June 1, 1994
Blood pressure-lowering effect of an orally active vasopressin V1 receptor antagonist in mineralocorticoid hypertension in the ratL M Burrell, P A Phillips, J M Stephenson, et al.
Clinical and Experimental Pharmacology & Physiology|March 1, 1994
Vascular endothelin responsiveness and receptor characteristics in vitro and effects of endothelin receptor blockade in vivo in cyclosporin hypertensionP A Phillips, K A Rolls, L M Burrell, et al.
Current Hypertension Reports|November 22, 2001
Evidence for cardioprotective, renoprotective, and vasculoprotective effects of vasopeptidase inhibitors in diseaseE Kubota, R G Dean, R A Hubner, et al.
Pageof 39